Is Vaxcyte, Inc. (PCVX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.4% / 30% | 18.1% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 1.4% / 33% | 18.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 3.9% / 33% | 52.0% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.4% / 33% | 18.1% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 3.9% / 33% | 52.0% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -25.6% | |
| Return on Assets (ROA) | -17.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$656M |
| Free Cash Flow | -$713M |
| Total Debt | $117M |
| Debt-to-Equity | 4.4 |
| Current Ratio | 7.9 |
| Total Assets | $3.0B |
Price & Trading
| Last Close | $54.71 |
| 50-Day MA | $55.67 |
| 200-Day MA | $43.09 |
| Avg Volume | 1.4M |
| Beta | 1.4 |
|
52-Week Range
$27.66
| |
About Vaxcyte, Inc. (PCVX)
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vaxcyte, Inc. (PCVX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vaxcyte, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vaxcyte, Inc.'s debt ratio?
Vaxcyte, Inc.'s debt ratio is 1.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.9%.
What are Vaxcyte, Inc.'s key financial metrics?
Vaxcyte, Inc. has a market capitalization of $7.7B. Return on equity stands at -25.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.